Literature DB >> 3336445

Neonatal myasthenia gravis: a new clinical and immunologic appraisal on 30 cases.

E Morel1, B Eymard, B Vernet-der Garabedian, C Pannier, O Dulac, J F Bach.   

Abstract

Anti-acetylcholine receptor (AChR) antibody titers, toxin binding blocking antibody, functional activity of serum on rat myotube cultures, IgG subclasses, and clinical data were studied in relation to the onset of neonatal myasthenia gravis (NMG) in 30 children of myasthenic mothers. Fourteen had NMG, including 4 atypical cases. Anti-AChR antibody titer was the best indication of NMG onset. NMG in a previous baby was also predictive. Pattern of IgG subclasses, presence of toxin-binding blocking antibodies, and serum functional activity were less predictive, but cast light on the mechanism of anti-AChR antibody pathogenicity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3336445     DOI: 10.1212/wnl.38.1.138

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis.

Authors:  M Oskoui; L Jacobson; W K Chung; J Haddad; A Vincent; P Kaufmann; D C De Vivo
Journal:  Neurology       Date:  2008-12-09       Impact factor: 9.910

Review 2.  The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.

Authors:  S J Tzartos; M T Cung; P Demange; H Loutrari; A Mamalaki; M Marraud; I Papadouli; C Sakarellos; V Tsikaris
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

3.  Binding and blocking antibodies to the human acetylcholine receptor: are they selected in various myasthenia gravis forms?

Authors:  E Morel; B Vernet-der Garabedian; B Eymard; F Raimond; F A Bustarret; J F Bach
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

4.  Neonatal myasthenia gravis: antigenic specificities of antibodies in sera from mothers and their infants.

Authors:  S J Tzartos; A Efthimiadis; E Morel; B Eymard; J F Bach
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

5.  New perspectives in multiple sclerosis.

Authors:  D W Paty
Journal:  Can Fam Physician       Date:  1989-10       Impact factor: 3.275

6.  Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function.

Authors:  S Riemersma; A Vincent; D Beeson; C Newland; S Hawke; B Vernet-der Garabedian; B Eymard; J Newsom-Davis
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

7.  Association of neonatal myasthenia gravis with antibodies against the fetal acetylcholine receptor.

Authors:  B Vernet-der Garabedian; M Lacokova; B Eymard; E Morel; M Faltin; J Zajac; O Sadovsky; M Dommergues; P Tripon; J F Bach
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

8.  Maternal myasthenia gravis: a cause for arthrogryposis multiplex congenita.

Authors:  Jana Midelfart Hoff; Anna Midelfart
Journal:  J Child Orthop       Date:  2015-10-19       Impact factor: 1.548

9.  Fetal acetylcholine receptor inactivation syndrome: A myopathy due to maternal antibodies.

Authors:  Yael Hacohen; Leslie W Jacobson; Susan Byrne; Fiona Norwood; Abhimanu Lall; Stephanie Robb; Robertino Dilena; Monica Fumagalli; Alfred Peter Born; Debbie Clarke; Ming Lim; Angela Vincent; Heinz Jungbluth
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-12-23

Review 10.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.